S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial

Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Compare

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
$0.19
-1.2%		$0.00
$0.11
▼
$0.89
$40.82M1.521.41 million shs332,766 shs
The Best High-Yield Dividend Stocks for 2024 Cover
The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
0.00%0.00%+3.61%-19.39%-38.26%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
0.706 of 5 stars		3.53.00.00.00.00.00.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
3.00
Buy$3.001,498.30% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
$1.10M37.11N/AN/A$0.09 per share2.09

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
-$22.94M-$0.12N/A∞N/AN/A-89.20%-72.15%5/8/2024 (Estimated)

Latest MTNB and HZD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/27/2024Q4 2023
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
N/A-$0.03-$0.03-$0.03N/AN/A    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
N/A
5.93
5.93

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
11.77%

Insider Ownership

CompanyInsider Ownership
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
9.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
34217.48 million196.61 millionNot Optionable

MTNB and HZD Headlines

SourceHeadline
Matinas Declines on Public OfferingMatinas Declines on Public Offering
msn.com - April 3 at 1:52 PM
Matinas BioPharma Prices $10 Million Registered Direct OfferingMatinas BioPharma Prices $10 Million Registered Direct Offering
globenewswire.com - April 3 at 8:30 AM
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call TranscriptMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript
finance.yahoo.com - April 1 at 3:38 PM
Matinas BioPharma Holdings, Inc.: Matinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
finanznachrichten.de - March 28 at 5:11 PM
Matinas BioPharma (NYSEAMERICAN:MTNB) Issues Earnings ResultsMatinas BioPharma (NYSEAMERICAN:MTNB) Issues Earnings Results
marketbeat.com - March 28 at 9:18 AM
Q4 2023 Matinas BioPharma Holdings Inc Earnings CallQ4 2023 Matinas BioPharma Holdings Inc Earnings Call
finance.yahoo.com - March 28 at 7:33 AM
MTNB Stock Earnings: Matinas BioPharma Hldgs Reported Results for Q4 2023MTNB Stock Earnings: Matinas BioPharma Hldgs Reported Results for Q4 2023
investorplace.com - March 27 at 11:03 PM
Matinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateMatinas BioPharma Reports 2023 Financial Results and Provides a Business Update
globenewswire.com - March 27 at 4:05 PM
Matinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationMatinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
finanznachrichten.de - March 25 at 10:12 AM
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationMatinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
globenewswire.com - March 25 at 8:00 AM
Why Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?Why Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?
finance.yahoo.com - March 22 at 3:59 PM
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseThree Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
finance.yahoo.com - March 22 at 10:59 AM
Three Patients with Invasive Fusarium Infection in Matinas BioPharmas Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseThree Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
globenewswire.com - March 22 at 9:15 AM
Matinas BioPharma Regains Compliance with NYSE American Continued Listing StandardsMatinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
globenewswire.com - March 22 at 6:30 AM
Matinas BioPharma Holdings, Inc. (MTNB)Matinas BioPharma Holdings, Inc. (MTNB)
uk.finance.yahoo.com - March 3 at 12:03 AM
Matinas BioPharma Holdings Inc.Matinas BioPharma Holdings Inc.
wsj.com - February 28 at 7:49 AM
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical ResolutionMatinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
finance.yahoo.com - February 26 at 8:27 AM
Matinas BioPharma Hldgs Stock (AMEX:MTNB) Dividends: History, Yield and DatesMatinas BioPharma Hldgs Stock (AMEX:MTNB) Dividends: History, Yield and Dates
benzinga.com - February 23 at 7:18 AM
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
finance.yahoo.com - February 20 at 8:14 AM
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
globenewswire.com - February 20 at 7:30 AM
AVBP ArriVent BioPharma, Inc.AVBP ArriVent BioPharma, Inc.
seekingalpha.com - February 4 at 7:38 AM
Matinas BioPharma Holdings Inc MTNBMatinas BioPharma Holdings Inc MTNB
morningstar.com - January 21 at 3:21 AM
Matinas BioPharma to Present at Biotech Showcase 2024Matinas BioPharma to Present at Biotech Showcase 2024
finance.yahoo.com - January 3 at 8:41 AM
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small OligonucleotidesMatinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
finance.yahoo.com - December 27 at 8:07 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Matinas BioPharma logo

Matinas BioPharma

NYSEAMERICAN:MTNB
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.